Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

Inclusion Criteria:

• Glaucoma or ocular hypertension in both eyes
• Currently being treated with latanoprost 0.005% QD
• IOP greater than or equal to 18mm Hg on latanoprost 0.005%
• Best-corrected VA of 20/200 or better in each eye
• Visual field within 6 months of study entry

Exclusion Criteria:

• Secondary glaucoma
• Active intraocular inflammation or macular edema
• Intraocular surgery or laser surgery within the past 3 months